Evotec SE filed its third-quarter and nine-month 2026 financial results on November 5, 2026, reporting Group revenue of €164.9 million for Q3 and €465.0 million for the first nine months, while reaffirming full-year guidance and detailing a 2030 financial framework.

Key Highlights

  • Q3 Group revenue: €164.9 million, with nine-month Group revenue of €465.0 million, according to the filing.
  • Adjusted Group EBITDA: -€1.6 million for Q3 and -€44.3 million for the first nine months, the company disclosed.
  • D&PD base business net sales increased 24% year-on-year in the first nine months of 2026, per the filing.
  • FY 2026 guidance reaffirmed: Expected Group revenue of €570 million to €610 million and adjusted Group EBITDA of -€105 million to -€70 million.
  • Horizon transformation: More than 20% of the €75 million annual run-rate savings target delivered by end of September, the company reported.
  • New CSO appointed: Dr. Joanna Holbrook succeeded Dr. Cord Dohrmann as Chief Scientific Officer, effective November 1, 2026.
  • 2030 framework: Around €1 billion in Group revenue by 2030, with an adjusted EBITDA margin of 20% targeted by year-end 2028.

Evotec's Q3 2026 Financial Results and Strategic Milestones

Evotec SE (NASDAQ:EVO) (Frankfurt Prime Standard: EVT) reported Q3 2026 Group revenue of €164.9 million and nine-month Group revenue of €465.0 million. At constant exchange rates (CER), the company disclosed Q3 revenue of €164.2 million and nine-month revenue of €477.4 million. Adjusted Group EBITDA came in at -€1.6 million for Q3 and -€44.3 million for the nine-month period, compared with -€1.7 million and -€39.1 million, respectively, at CER. The company's full-year 2026 guidance calls for Group revenue of €570 million to €610 million (€595 million to €635 million at CER) and adjusted Group EBITDA of -€105 million to -€70 million (-€90 million to -€60 million at CER).

According to the filing, Horizon transformation progress is ahead of plan. By the end of September, Evotec had delivered more than 20% of the €75 million in annual run-rate savings targeted by end of 2027, already within the 20-30% contribution planned for full-year 2026. Approximately half of the planned workforce reductions have been implemented, the company reported, and three of four planned site closures are expected to be completed by year-end, with the fourth expected in the first quarter of 2027.

On the business development side, the filing noted that Just - Evotec Biologics was selected by Vertex Pharmaceuticals for commercial manufacturing of povetacicept at its J.POD Redmond facility. In September 2026, a Phase 1 clinical trial of JST-018, an investigational antibody cocktail developed in collaboration with the U.S. Department of War, was initiated. New research collaborations with Plectonic (entered September 2026) and Odyssey Therapeutics (entered August 2026) were also disclosed. The 2030 framework detailed in the filing targets approximately €1 billion in Group revenue, with Just - Evotec Biologics and D&PD base business each expected to contribute approximately 40%, and D&PD strategic partnerships and innovation activities approximately 20%.

What Was Disclosed

Evotec SE disclosed Q3 and nine-month 2026 financial results, reaffirmed full-year guidance, provided a 2030 revenue and profitability framework, reported Horizon transformation milestones, announced new commercial partnerships, and named Dr. Joanna Holbrook as Chief Scientific Officer effective November 1, 2026.